Scarica l'app Stockscreener
1.65
13.01%
0.19
Dopo l'orario di chiusura:
1.65
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CTXR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.46
Aprire:
$1.61
Volume 24 ore:
121.98K
Relative Volume:
0.05
Capitalizzazione di mercato:
$17.55M
Reddito:
-
Utile/perdita netta:
$-39.14M
Rapporto P/E:
-0.2764
EPS:
-5.97
Flusso di cassa netto:
$-28.20M
1 W Prestazione:
+10.74%
1M Prestazione:
+60.19%
6M Prestazione:
-47.62%
1 anno Prestazione:
-92.90%
Intervallo 1D:
$1.61
$1.67
Intervallo di 1 settimana:
$1.4009
$1.67
Portata 52W:
$0.65
$26.25
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Nome
Citius Pharmaceuticals Inc
Settore
Industria
Telefono
(908) 967-6676
Indirizzo
11 COMMERCE DRIVE, CRANFORD, NJ
Confronta CTXR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
1.65 | 16.31M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-30 | Aggiornamento | D. Boral Capital | Hold → Buy |
| 2021-11-30 | Iniziato | Maxim Group | Buy |
Citius Pharmaceuticals Inc Borsa (CTXR) Ultime notizie
What drives Citius Pharmaceuticals Inc. stock priceHigh-yield portfolio picks - Autocar Professional
Is Citius Pharmaceuticals Inc. a good long term investmentFree Stock Market Knowledge Sharing - Autocar Professional
What analysts say about Citius Pharmaceuticals Inc. stockRecord-setting profit potential - jammulinksnews.com
Citius Pharmaceuticals Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com
Citius Oncology Announces Closing of $9.0 Million Public Offering - Eastern Progress
Citius Oncology closes $9 million public offering to support LYMPHIR - Investing.com Australia
Citius Oncology closes $9 million public offering to support LYMPHIR By Investing.com - Investing.com Nigeria
Citius Oncology Raises $9M in Public Offering for LYMPHIR Commercialization - AInvest
Citius Oncology Announces Pricing Of $9M "Reasonable Best-Efforts" Public Offering Of 6,818,182 Shares Of Common Stock And Warrants To Purchase Shares Of Common Stock At A Public Offering Price Of $1.32 Per Share - 富途牛牛
Cencora distribution deal boosts Citius shares - MSN
Citius Pharmaceuticals shares fall 1.34% after-hours following Citius Oncology's public offering. - AInvest
Citius Oncology Announces Pricing of $9.0 Million Public Offering - Finansavisen
Citius Oncology (CTOR): Is LYMPHIR's Launch Priced for Success? - AInvest
Citius Oncology: Is A Lymphir Launch Coming Too Late? - Seeking Alpha
Citius Pharmaceuticals (CTXR) Surges on New Distribution Deal - GuruFocus
Citius Oncology stock rises after expanding LYMPHIR distribution network By Investing.com - Investing.com Nigeria
Citius Oncology stock rises after expanding LYMPHIR distribution network - Investing.com Australia
Citius Oncology Expands Lymphir Distribution With Cencora - MarketScreener
Citius Oncology expands distribution network for LYMPHIR with Cencora - Investing.com Australia
Citius Oncology expands distribution network for LYMPHIR with Cencora By Investing.com - Investing.com Canada
Citius stock gains on Cencora distribution deal (CTXR:NASDAQ) - Seeking Alpha
Pre-market Movers: KAPA, CYCC, SONN, RANI... - RTTNews
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora - WV News
Citius Pharmaceuticals Soars 10.18% on Nasdaq Compliance - AInvest
Citius Pharmaceuticals' Strategic Financing: Balancing Dilution Risks with LYMPHIR's Commercial Potential - AInvest
Citius Oncology Plans Stock Offering; Shares Down - MarketScreener
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) On The Verge Of Breaking Even - simplywall.st
Citius Pharmaceuticals regains Nasdaq compliance - MSN
Citius Pharmaceuticals Regains Nasdaq Compliance - The Globe and Mail
CTXR SEC FilingsCitius Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Citius Pharmaceuticals regains Nasdaq compliance after 10-day streak - Investing.com
Citius Pharmaceuticals regains Nasdaq compliance after 10-day streak By Investing.com - Investing.com UK
Citius Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement - 富途牛牛
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - Finansavisen
Citius Pharmaceuticals: LYMPHIR Launch Ignites High-Growth Potential in CTCL Market - AInvest
Citius Pharmaceuticals Prepares for Q2 2025 Commercial Launch of FDA-Approved Cancer Drug LYMPHIR - Insider Monkey
Citius Pharmaceuticals Inc Azioni (CTXR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):